CD79A and bronchiectasis: In receiver operating characteristic curve analyses, the antiglycopeptidolipid core IgA antibody level demonstrated excellent performance in diagnosing NTM-PD in all study participants (n = 282; area under the curve, 0.885; 95% CI, 0.799-0.971), diagnosing NTM-PD in the bronchiectasis cohort (n = 240; area under the receiver operating characteristic curve, 0.886; 95% CI, 0.800-0.973), and in differentiating NTM-PD from NTM isolation (n = 44; area under the receiver operating characteristic curve, 0.816; 95% CI, 0.687-0.945) (Fig 3).